Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor

Lung

Lung
2025-02-21T00:00:00.000+11:00
Ongoing

RAD204

RAD204
Lung

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours.

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium -177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Solid Tumours.

Trial overview

Clinical Area

Theranostics

Disease

Lung

Disease site

Lung & bronchus

Study Phase

0

Trial Identifiers

Registration number: NCT06305962

https://clinicaltrials.gov/study/NCT06305962

GenesisCare Location(s)
Principal Investigator(s)
Nuclear Medicine Physician

Prof. Joe Cardaci

MBBS, FRACP, AANNMS

Prof. Joe Cardaci
location pin icon

Murdoch (Oncology)

View Profile
Profile Image - Prof. Joe Cardaci

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.